Crohn's the third indication for Skyrizi after psoriasis and psoriatic arthritis, and a key step in AbbVie's aim to grow the drug – already one of its top sellers with sales of almost $3 billion ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Skyrizi (risankizumab-rzaa) is prescribed for Crohn’s disease and certain other inflammatory conditions. As with other drugs, Skyrizi can cause side effects, such as headache and injection site ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

In Crohn's, Skyrizi, Stelara, and Ilumya are already approved by the FDA, while Tremfya is under review, having been submitted to the regulator last June. In the VIVID-1 trial, patients treated ...